What is EpimAb Biotherapeutics, Inc.'s contact information?

EpimAb Biotherapeutics, Inc.'s contact information: contact@epimab.com, +862161951000.

How many employees does EpimAb Biotherapeutics, Inc. have?

EpimAb Biotherapeutics, Inc. has 40 employees.

What industry does EpimAb Biotherapeutics, Inc. belong to?

EpimAb Biotherapeutics, Inc. is in the industry of: Biotechnology.

What are EpimAb Biotherapeutics, Inc.'s official social media profiles?

EpimAb Biotherapeutics, Inc. Linkedin Page EpimAb Biotherapeutics, Inc. Twitter Page

What are EpimAb Biotherapeutics, Inc.'s office addresses?

EpimAb Biotherapeutics, Inc. has 2 known office addresses: Room 205, Building No.5, No. 338 Jia Li Lue Road, Zhangjiang Hi-Tech Park, Shanghai, Shanghai, Shanghai, 201203, CN Room 205, Building No.5, No. 338 Jia Li Lue Road, Zhangjiang Hi-tech Park, Shanghai, Shanghai, Shanghai 201203, Cn.

What is EpimAb Biotherapeutics, Inc.'s estimated annual revenue?

EpimAb Biotherapeutics, Inc.'s revenue is $9,300,000

What is EpimAb Biotherapeutics, Inc.'s open headcount?

EpimAb Biotherapeutics, Inc. has no job postings yet.

What is the number of ad campaigns for EpimAb Biotherapeutics, Inc.?

EpimAb Biotherapeutics, Inc. has no advertisements yet.

What is the number of recent news articles about EpimAb Biotherapeutics, Inc.?

EpimAb Biotherapeutics, Inc. has one news article.

EpimAb Biotherapeutics, Inc. - Pubrio Company Profile & Intent

EpimAb Biotherapeutics, Inc.

China · Biotechnology

Biotechnology

EpimAb Biotherapeutics, Inc., is a China-based, privately held, start-up company founded in 2015 that is developing a portfolio of novel bi-specific antibodies in oncology and immune-oncology. All bispecifics are based on a proprietary platform, FIT-Ig (Fabs in Tandem). Multiple FIT-Igs have already been successfully generated binding to small, large, soluble or membrane-bound antigens with biochemical and biophysical properties similar to their parent monospecific antibodies. The first molecule, EMB-01, is a cMET/EGFR-inhibitor, that is in CMC development in collaboration with WuXi Apptec. EpimAb also has concluded licensing arrangements, e.g. with Kymab and Innovent Biologics, and is open to further partnerships. EpimAb has successfully concluded a Series A round of $25 MM with a consortium of international investors.